Filing Flows › Health Care › Biocryst Pharmaceuticals (BCRX)
Biocryst Pharmaceuticals (BCRX) earnings and revenue breakdown
Latest: Q3 2026 · 10-Q filed Nov 4, 2026 · Biocryst Pharmaceuticals (BCRX) Q3 2026 earnings results →
Q3 2026 Revenue up 13% year over year to $180M · 21¢ of every $1 of revenue kept as net profit · operating margin 29.6%
Biocryst Pharmaceuticals made $180M in Q3 2026 (+13% Y/Y): Product $172M, License and other revenues $8.0M. Operating margin 29.6%, net earnings $37.9M. See where every dollar goes — costs, profit and cash — as a Sankey from the 10-Q filed Nov 4, 2026.
Drawing the Sankey…
Open the interactive Sankey → click any line for what the company wrote about it, compare Y/Y and Q/Q, export as PNG or PDF
What changed this quarter
Revenue was $180.3M in Q3 2026, up 13% year over year and down 17% from the previous quarter. Product was the largest line at 96% of revenue. Product added $14.6M year over year (up 9%), 70% of the total change.
Operating profit was $53.3M, a 29.6% margin (up 11.0 points year over year). Of the extra revenue versus Q3 2025, 114% reached operating profit, above the 19% margin then. Total costs fell 2% while revenue rose 13%. The fastest-growing cost line was Research & development (+31%). Net earnings were $37.9M, up 194% year over year. The effective tax rate was 1.7%.
Operating cash flow was $33.0M (down 21% year over year), 87% of net earnings. Non-cash charges added back $244K of depreciation and amortization and $14.2M of share-based compensation. Working capital and other items used $19.4M. Capital expenditures of $233K left free cash flow of $32.8M.
Quarterly history
| Quarter | Form | Filed | Revenue | Y/Y | Op. margin | Net earnings | Op. cash flow |
|---|---|---|---|---|---|---|---|
| Q3 2026 | 10-Q | Nov 4, 2026 | $180M | +13% | 29.6% | $37.9M | $33.0M |
| Q2 2026 | 10-Q | Aug 5, 2026 | $218M | +34% | 45.1% | $78.4M | $104M |
| Q1 2026 | 10-Q | May 6, 2026 | $156M | +8% | -448.6% | −$722M | −$61.8M |
| Q4 2025 | 10-K | Feb 26, 2026 | $407M | +209% | 64.0% | $246M | $292M |
| Q3 2025 | 10-Q | Nov 4, 2025 | $159M | +36% | 18.6% | $12.9M | $41.6M |
| Q2 2025 | 10-Q | Aug 5, 2025 | $163M | +49% | 18.2% | $5.1M | $41.3M |
| Q1 2025 | 10-Q | May 6, 2025 | $146M | +57% | 14.6% | $32K | −$27.5M |
Charts
Interactive views
The same charts as the app — open one to draw it.
💵Where each $1 goesinteractive
Loading the interactive chart…
🌏Named in Asian annual reportsinteractive
Loading the interactive chart…
🔄Rotation against the market and its industry (RRG)interactive
Loading the interactive chart…
🔍Earnings qualityinteractive
Loading the interactive chart…
⚖️Fair value by methodinteractive
Loading the interactive chart…
🔭Outlook & guidanceinteractive
Loading the interactive chart…
📈Investments: gains and what it boughtinteractive
Loading the interactive chart…
🏭Its industry’s money flow (input-output)interactive
Loading the interactive chart…
About Biocryst Pharmaceuticals
We are a global biotechnology company focused on developing and commercializing medicines for hereditary angioedema (“HAE”) and other rare diseases, driven by our deep commitment to improving the lives of people living with these conditions. We have built a robust commercial infrastructure to support the successful commercialization of ORLADEYO, an oral, once-daily therapy discovered and developed internally for the prevention of HAE attacks. Our business strategy includes leveraging this established commercial platform to successfully commercialize a pipeline of potential first-in-class or best-in class oral small molecule and injectable protein therapeutics targeting a range of rare diseases. These programs are being pursued through both internal discovery efforts and strategic business development.
In its own words, from its 10-K, filed Feb 26, 2026.
Biocryst Pharmaceuticals against its Biological Products, (No Diagnostic Substances) peers
The largest companies of the same SEC industry, each at its latest quarter. Revenue growth: +13% against the peers' median +13%. Operating margin: 29.6% against the peers' median 35.8%.
| Company | Quarter | Revenue | Y/Y | Op. margin |
|---|---|---|---|---|
| BCRX Biocryst Pharmaceuticals | Q3 2026 | $180M | +13% | 29.6% |
| AMGN Amgen | Q3 2026 | $10.4B | +8% | 35.8% |
| GILD Gilead Sciences | Q3 2026 | $8.3B | +7% | 41.7% |
| BIIB Biogen | Q3 2026 | $2.8B | +11% | -0.3% |
| MRNA Moderna | Q3 2026 | $1.3B | +29% | 9.9% |
| NBIX Neurocrine Biosciences | Q3 2026 | $1.1B | +41% | 29.5% |
| EXEL Exelixis | Q3 2026 | $659M | +10% | 40.8% |
| HALO Halozyme Therapeutics | Q3 2026 | $493M | +39% | 59.8% |
| MGTX MeiraGTx Holdings | Q2 2026 | $321M | 87× | 76.0% |
Source: Biocryst Pharmaceuticals 10-Q on SEC EDGAR · CIK 882796 · Biological Products, (No Diagnostic Substances)
Guidance and outlook
13F: who owns BCRX and who is buying
More on BCRX
- How Biocryst Pharmaceuticals makes money: revenue by segment
- Biocryst Pharmaceuticals next earnings date and what analysts expect
- Biocryst Pharmaceuticals stock forecast, price target and fair value
- Who owns Biocryst Pharmaceuticals stock: holders, funds and Congress trades
- Biocryst Pharmaceuticals guidance and outlook
- Biocryst Pharmaceuticals recalls, complaints and regulation
History
Every quarter: Q3 2026 results · Q2 2026 results · Q1 2026 results · Q4 2025 results · Q3 2025 results · Q2 2025 results · Q1 2025 results
- Biocryst Pharmaceuticals guidance history: guided vs reported
- Biocryst Pharmaceuticals operating margin by quarter
- Biocryst Pharmaceuticals net income by quarter
- Biocryst Pharmaceuticals free cash flow by quarter
- Biocryst Pharmaceuticals R&D spending by quarter
- Biocryst Pharmaceuticals capital expenditures by quarter